ArticleBreast cancer research : BCR2025
Integrative multi-omics reveals common and distinct pathogenic mechanisms and preoperative diagnostic signatures in breast fibroepithelial lesions.
Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Breast fibroepithelial lesions (FELs) comprising fibroadenomas (FAs) and phyllodes tumors (PTs) with varying degrees of malignancy, necessitate tailored surgical approaches. However, preoperative diagnosis of FELs remains challenging and their pathogenesis is not fully elucidated. By integrating methylation and expression data, we revealed substantial molecular deregulation common to FAs and PTs, impacting pathways central to genetic information processing and metabolism. Furthermore, we identified 86 genes exhibiting concurrent differential expression and methylation changes between FAs and PTs, some of which have been implicated in the malignant progression of disease. Subsequently, we constructed two gene-pair signatures: one comprising 158 pairs for distinguishing FAs from PTs, and another with 146 pairs for differentiating benign from malignant PTs. Both signatures achieved AUC exceeding 0.85 in independent surgical and core biopsy datasets. Finally, we identified 99 pathogenic genes exhibiting continuous up-regulation or down-regulation from FAs to malignant PTs. Significant associations were observed between these genes and key cancer-related biological pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.